title: Targeted therapies in bone sarcomas: current approach and future directions.
abstract: BACKGROUND
  Bone sarcomas are rare malignancies and once advanced, there is limited response to current chemotherapeutic regimens. Targeted therapies could have substantial impact on these diseases.
  
  
  METHODS
  Specific molecular targets of bone sarcomas are reviewed along with the various targeted therapies that have potential to change the outcome of these chemotherapy resistant diseases.
  
  
  CONCLUSIONS
  There are promising pathways identified that targeted inhibitors could provide better treatment options for metastatic bone sarcomas. There is a strong need for continued Phase II and III clinical trials investigating these molecularly targeted therapies.
authors.affiliation: Northwestern Memorial Hospital, Internal Medicine, Chicago, IL 60611, USA. yarberjl@gmail.com
authors.forename: Jessica Lee
authors.initials: JL
authors.lastname: Yarber
authors.forename: Mark
authors.initials: M
authors.lastname: Agulnik
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000378:metabolism; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism; D002986:Clinical Trials as Topic / Q000379:methods / Q000639:trends; D016503:Drug Delivery Systems / Q000379:methods*; D005544:Forecasting; D006801:Humans; D012516:Osteosarcoma / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism
chemical_list: D000970:Antineoplastic Agents